Skip to main content

Market Overview

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study

Share:
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
  • Nektar Therapeutics Inc (NASDAQ: NKTRhas entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study.
  • The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients.
  • NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid tumors.
  • Avelumab is marketed in the U.S. as Bavencio, is co-developed and co-commercialized by Merck KGaA and Pfizer.
  • The study will begin enrolling patients in Q1 of 2022.
  • Price Action: NKTR shares are up 4.53% at $17.08 during the market session on the last check Tuesday.
 

Related Articles (MKGAF + MKKGY)

View Comments and Join the Discussion!

Posted-In: bladder cancerBiotech News Health Care Contracts Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com